BRTX vs PATH
BioRestorative Therapies Inc (BRTX) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
BioRestorative Therapies Inc (BRTX) is a biotechnology company listed on NASDAQ.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported BRTX revenue for 2024-12-31 was $401.0K. Net income was -$9.0M. Revenue was up 175.0% from 2023-12-31 to 2024-12-31. BRTX currently screens at market cap $10.2M.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
BRTX currently screens at market cap $10.2M. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the BRTX and PATH stock pages for the full models.
Not investment advice.